Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BK-01 adjuvanted influenza vaccine in adults
NCT07349017Phase 1Not yet recruiting
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Feb 2026
- Primary completion
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of influenza vaccine (BK-01 adjuvant) in influenza (4 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Incidence rate of adverse reactions/events after administration at 30 days. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
influenza vaccine (BK-01 adjuvant)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07349017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349017.